Critically injured patients endure a period of hypermetabolism/catabolism after being
resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor
wound healing, susceptibility to infection and long hospital stays. While there have been
some data to suggest that hypermetabolism can be ameliorated in burn patients by beta
blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our
hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose
control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of
critically injured patients.
Phase:
Phase 2
Details
Lead Sponsor:
Denver Health and Hospital Authority National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)